The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
14-(pyridin-3-yl)-7,8,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one ID: ALA5286877
Max Phase: Preclinical
Molecular Formula: C23H18N4O
Molecular Weight: 366.42
Associated Items:
Names and Identifiers Canonical SMILES: O=C1c2ccccc2N(c2cccnc2)C2c3[nH]c4ccccc4c3CCN12
Standard InChI: InChI=1S/C23H18N4O/c28-23-18-8-2-4-10-20(18)27(15-6-5-12-24-14-15)22-21-17(11-13-26(22)23)16-7-1-3-9-19(16)25-21/h1-10,12,14,22,25H,11,13H2
Standard InChI Key: XJLRHHNAIDHTRS-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 33 0 0 0 0 0 0 0 0999 V2000
-3.2308 0.9533 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5162 1.3656 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.8044 0.9538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.8044 0.1286 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5144 -0.2831 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2308 0.1249 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0197 -0.1263 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.5346 0.5411 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0196 1.2087 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.6839 1.9625 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1367 2.0487 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.6217 1.3811 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.2860 0.6273 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7709 -0.0403 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.5916 0.0458 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9273 0.7996 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4424 1.4673 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8549 2.1818 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.7455 0.8850 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2308 0.2173 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8984 -0.5334 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.0789 -0.6244 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3584 -0.7549 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7708 -1.4697 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3588 -2.1818 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.4666 -2.1818 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8785 -1.4715 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.4703 -0.7549 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
6 5 2 0
1 6 1 0
4 7 1 0
8 7 1 0
9 8 2 0
3 9 1 0
9 10 1 0
11 10 1 0
12 11 1 0
13 12 1 0
8 13 1 0
13 14 1 0
14 15 1 0
15 16 2 0
16 17 1 0
12 17 1 0
17 18 2 0
16 19 1 0
20 19 2 0
21 20 1 0
22 21 2 0
15 22 1 0
23 14 1 0
24 23 2 0
25 24 1 0
26 25 2 0
27 26 1 0
28 27 2 0
23 28 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 366.42Molecular Weight (Monoisotopic): 366.1481AlogP: 4.41#Rotatable Bonds: 1Polar Surface Area: 52.23Molecular Species: NEUTRALHBA: 3HBD: 1#RO5 Violations: ┄HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 5.28CX LogP: 3.65CX LogD: 3.65Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.54Np Likeness Score: -0.38
References 1. Hao X, Deng J, Zhang H, Liang Z, Lei F, Wang Y, Yang X, Wang Z.. (2021) Design, synthesis and bioactivity evaluation of novel N-phenyl-substituted evodiamine derivatives as potent anti-tumor agents., 55 [PMID:34990980 ] [10.1016/j.bmc.2021.116595 ]